U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Active, not recruiting · Phase 1 · NCT03260491
Conditions: Non-Small Cell Lung Cancer (NSCLC)
At a glance
- Research payments reported, 2025
- $442,209
- U.S. investigators named
- 11
- Sites paid
- 12
- Planned or actual enrollment
- 312
About the trial
- Sponsor
- Daiichi Sankyo (with Merck Sharp & Dohme LLC)
- Tested
- HER3-DXd (FL-DP) (drug), HER3-DXd (CTM-1 Lyo-DP) (drug), HER3-DXd (CTM-3 Lyo-DP) (drug)
- Dates
- Started 2017-10-30; completion 2027-07-30
- Results posted
- Not yet
This study was designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion. In Dose Escalation, HER3-DXd was evaluated in participants with metastatic or unresectable NSCLC with epidermal growth factor receptor (EGFR) activating mutation after disease progression during/after EGFR tyrosine kinase inhibitor (TKI) therapy. In Dose Expansion, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCLC (ie, without EGFR-activating mutations) with disease progression during/after systemic treatment for locally advanced or metastatic disease. In addition, HER3…
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $442,209 in research payments for this study in 2025 (389 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kathryn A. Gold, MD Medical Oncology · La Jolla, CA
- Conor E. Steuer, MD Hematology & Oncology · Atlanta, GA
- Pasi Antero Janne, MD PHD Medical Oncology · Boston, MA
- Shirish M. Gadgeel, MD Medical Oncology · Detroit, MI
- Helena Yu, MD Internal Medicine · New York, NY
- Nashat Gabrail, M.D. Specialist · Canton, OH
- Liza C. Villaruz, M.D. Internal Medicine · Pittsburgh, PA
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- Ricardo H. Alvarez, MD Medical Oncology · Houston, TX
- Christina S. Baik, M.D. Medical Oncology · Seattle, WA
- Jorge M. Chaves, M.D. Hematology & Oncology · Tacoma, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Exigent Research Llc $104,507
- University of California San Diego $82,194
- Emory University Hospital, GA $52,729
- Gabrail Cancer Research Center $48,959
- UPMC Hillman Cancer Center $46,286
- Dana-Farber Cancer Institute $29,133
- University of Washington Medical Ctr, WA $25,452
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $20,384
- Sarah Cannon Research Institute $15,848
- Henry Ford Health Hospital, MI $14,436
- Northwest Medical Specialties - Tacoma $1,724
- Seattle Cancer Care Alliance $556
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.